非小细胞肺癌术后辅助化疗的进展
비소세포폐암술후보조화료적진전
Advance of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer
  • 万方数据
    医学信息 의학신식
    MEDICAL INFORMATION
    2015年 24期 388-389 ,共2页

    刘博%杨双强

    류박%양쌍강

    肺肿瘤%辅助化疗%生物标志物 肺腫瘤%輔助化療%生物標誌物
    폐종류%보조화료%생물표지물
    Lung neoplasms%Adjuvant chemotherapy%Biomarker
    肺癌是全球癌症相关死亡的主要病因之一，可分为非小细胞肺癌(non-smal cel lung cancer, NSCLC)和小细胞肺癌。本文就NSCLC患者术后辅助化疗地位的确定、化疗方案的选择、合适的化疗人群以及生物标志物的研究进展进行综述。
    폐암시전구암증상관사망적주요병인지일，가분위비소세포폐암(non-smal cel lung cancer, NSCLC)화소세포폐암。본문취NSCLC환자술후보조화료지위적학정、화료방안적선택、합괄적화료인군이급생물표지물적연구진전진행종술。
    Lung cancer is one of the main causes of cancer-related deaths al over the worldwide, which is divided into non-smal cel lung cancer (NSCLC) and smal cel lung cancer. This review is mainly focus on discussing the role of postoperative chemotherapy, the choice of chemotherapy regimens, the appropriate chemotherapy group and the research progress on biomarker.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문